Drug
Linvoseltamab clinical trials
Also written REGN5458 and Lynozyfic™.
- studies test it
- 18
- open now
- 15
- in phase 3
- 5
- first study started
- 2019
Keep track of what changes. Save the linvoseltamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 12
- Phase 3
- 5
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 6
Regeneron Pharmaceuticals (12) · Dickran Kazandjian, MD (2) · Medical College of Wisconsin (1) · Multiple Myeloma Research Consortium (1) · Fred Hutchinson Cancer Center (1) · European Myeloma Network B.V. (1)
Often tested with
Tested in the same studies.
Dupilumab (1) · Carfilzomib (1) · Tocilizumab (1) · Lenalidomide (1)
Studies
Open first, then newest update. How each study uses linvoseltamab is read from its arms, and is right about nine times in ten.
Testing it · 18
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingPhase 3Regeneron PharmaceuticalsNCT07222761Written as Linvoseltamab
- A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)RecruitingPhase 3Regeneron PharmaceuticalsNCT07393282Written as Linvoseltamab
- A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaRecruitingPhase 3Regeneron PharmaceuticalsNCT05730036Written as Linvoseltamab
- Horizon Two: HR NDMM (MMRC-100)RecruitingPhase 2Multiple Myeloma Research ConsortiumNCT07053436Written as Bispecific Monoclonal Antibody and Triplet Therapy
- Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)RecruitingPhase 4Regeneron PharmaceuticalsNCT07609940Written as Linvoseltamab
- Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple MyelomaRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT07181941Written as Linvoseltamab
- A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)RecruitingPhase 1/2Regeneron PharmaceuticalsNCT06292780Written as Linvoseltamab
- IMMUNOPLANT for Newly Diagnosed Multiple MyelomaRecruitingPhase 2Dickran Kazandjian, MDNCT06376526Written as Linvoseltamab
- BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)Not yet recruitingPhase 2Medical College of WisconsinNCT07009899Written as Linvoseltamab
- A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple MyelomaRecruitingPhase 1/2Regeneron PharmaceuticalsNCT06669247Written as Linvoseltamab
- A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple MyelomaRecruitingPhase 2Regeneron PharmaceuticalsNCT06140524Written as Linvoseltamab
- A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received TreatmentRecruitingPhase 1/2Regeneron PharmaceuticalsNCT05828511Written as Linvoseltamab
- Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1/2Regeneron PharmaceuticalsNCT03761108Written as Linvoseltamab
- A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for TransplantRecruitingPhase 3European Myeloma Network B.V.NCT06932562Written as Linvoseltamab
- Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After RelapseRecruitingPhase 2Dickran Kazandjian, MDNCT06910124Written as Linvoseltamab
- Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food AllergyActive, not recruitingPhase 1Regeneron PharmaceuticalsNCT06369467Written as linvoseltamab
- A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)WithdrawnPhase 2/3Regeneron PharmaceuticalsNCT07428369Written as Linvoseltamab
- A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple MyelomaActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT05955508Written as Linvoseltamab
Given in every arm · 2 — linvoseltamab is usual care beside what is tested
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMRecruitingPhase 3Dana-Farber Cancer InstituteNCT07624513Written as Linvoseltamab
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Linvoseltamab
As the comparator · 1 — what is tested is compared with linvoseltamab
Codes
What other systems call linvoseltamab · ClinicalTrials.gg INT002143
- MeSH (NLM) C000731817linvoseltamabOne source NLM
- UNII (FDA) M3CPC50MZSLINVOSELTAMABConfirmed FDA, NLM, Wikidata
- Wikidata Q133445837linvoseltamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C158504LinvoseltamabOne source FDA
- DrugBank DB17447One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731817 | linvoseltamab | One source NLM |
| UNII (FDA) | M3CPC50MZS | LINVOSELTAMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q133445837 | linvoseltamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C158504 | Linvoseltamab | One source FDA |
| DrugBank | DB17447 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.